HFA Premium Access

Late Breaking Trials II: Focus on chronic heart failure

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure
Topic: Miscellaneous
Session type: Special Session
Date: 30 April 2017
Time: 08:30 - 10:00

Session

12 presentations in this session

The which heart failure intervention is most cost-effective in reducing hospital stay trial.

Speaker: Professor S. Stewart (Adelaide, AU)
Thumbnail

Discussion: The which heart failure intervention is most cost-effective in reducing hospital stay trial.

Thumbnail

Global variations in mortality among patients with heart failure.

Speaker: Doctor H. Dokainish (Hamilton, CA)
Thumbnail

Discussion: Global variations in mortality among patients with heart failure.

Thumbnail

Heart failure with mid ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire EF spectrum.

Speaker: Professor L. Lund (Stockholm, SE)
Thumbnail

Discussion: CHARM.

Thumbnail

Empagliflozin decreases risk of kidney function decline in type 2 diabetes: slope analyses in patients with and without heart failure at baseline from the EMPA-REG OUTCOME trial.

Speaker: Professor A. Cheung (Salt Lake City, US)
Thumbnail

Discussion: EMPA-REG OUTCOME.

Thumbnail

Targeting heart rate to improve mortality in heart failure with reduced ejection fraction: a comparison of sinus rhythm and atrial fibrillation.

Speaker: Professor J. Cleland (Glasgow, GB)
Thumbnail

Discussion: Targeting heart rate to improve mortality in heart failure with reduced ejection fraction: a comparison of sinus rhythm and atrial fibrillation.

Thumbnail

6 speakers from this session

Professor Simon Stewart

University of Notre Dame Australia, Adelaide (Australia)
7 presentations
0 follower

Doctor Hisham Dokainish

McMaster University, Hamilton (Canada)
7 presentations
1 follower

Professor Lars Lund

Karolinska Institute, Stockholm (Sweden)
46 presentations
1 follower

Professor Alfred Cheung

, Salt Lake City (United States of America)
1 presentation
0 follower

Professor John Cleland

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)
56 presentations
2 followers

Professor Michel Komajda

Groupe Hospitalier Paris Saint-Joseph, Paris (France)
31 presentations
0 follower

This platform is supported by

logo Novo Nordisk